Fenofibrate or omega-3 fatty acid use is associated with lower long term outcomes from propensity matched analysis of 141972 patients with diabetes in Korean national health insurance cohort. (25th November 2020)

• Record Type: Journal Article
• Authors: Jo, S.H; Kim, H.S; Han, S.J; Kim, S.A
• Is Part Of: European heart journal. Volume 41:(2020)Supplement 2
• Publication Date: 2020-11-25
• Subjects: Lipid-Lowering Agents; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/ehjci/ehaa946.3336
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Background: We investigated the clinical effectiveness of fenofibrate or omega 3-fatty acid in patients with diabetes for long term. Methods: Using Korean National Health Insurance data base, 141972 eligible patients with diabetes were selected. We divided the patients into 2 groups with propensity matching 1:2 ratio, fenofibrate/omega 3 fatty acid users (Fen-O, n=42353) or no users (n=14880). We followed up for 6-years for primary endpoint of death, myocardial infarction (MI), stroke and individual outcomes including cardiac death. Results: Primary endpoint was significantly lower in Fen-O group as compared to no users, 2.35% vs. 1.58% (HR 0.673, CI: 0.633–0.715, P<0.001) in crude and 2.35% vs. 1.58% (HR 0.641, CI: 0.565–0.728) after adjusting age, sex, medical history analysis, body mass index, LDL-C and HDL-C). All cause death (0.76% vs. 1.24% [HR 0.664, CI: 0.625–0.706], p<0.0001), cardiac death (0.11% vs. 1.19% [HR 0.610, CI: 0.486–0.765, p=0.0001) and stroke (0.57% vs. 0.79%, [HR 0.723, CI: 0.594–0.881, P=0.0013) were significantly lower in Fen-O group. In the survival analysis, Fen-O group showed significantly lower primary outcome rate which is proportional with the days of intaking fenofibrate or omega 3 fatty acid (log rank <0.001), Conclusions: Use of fenofibrate or omega 3 fatty-acid was associated with lower rate of composite of death, MI, stroke in diabetes patient for 6 year follow-up with large population. Funding Acknowledgement: Type of funding source: None